Fig. 2: Pathological response in operated patients and in molecular and clinical subgroups. | Nature Medicine

Fig. 2: Pathological response in operated patients and in molecular and clinical subgroups.

From: Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial

Fig. 2

a, Pathological response distribution in the full cohort according to Becker classification. pCR indicates no residual tumor (TRG1a); subtotal regression (pSR, TRG1b) reflects ≥90% tumor regression; partial response (pPR, TRG2) indicates 50–90% regression; minor response (pMR, TRG3) corresponds to <50% regression. Solid segments indicate minimal regression, while dotted outlines indicate maximal estimated regression according to Becker classification. b, pCR rate in patients with available PD-L1 CPS data (n = 27), stratified by CPS 0, ≥1, 1–9 and ≥10. c, pCR rate stratified by HER2 expression (HER2 IHC 3+ versus HER2 2+/ISH+). d, pCR stratified by tumor stage (T1/2 versus T3/4); one tumor was classified as Tx (n = 30). The complete response rate is depicted by bars, and the upper limit of the 95% CI interval is shown.

Back to article page